BioHarvest Sciences (NASDAQ:BHST - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.05), Zacks reports. The firm had revenue of $7.17 million during the quarter, compared to analysts' expectations of $7.24 million.
BioHarvest Sciences Stock Performance
NASDAQ BHST traded down $0.20 during trading on Friday, hitting $5.54. 21,569 shares of the company's stock traded hands, compared to its average volume of 8,878. BioHarvest Sciences has a 12-month low of $5.53 and a 12-month high of $7.38. The business's fifty day moving average price is $5.70. The firm has a market cap of $90.99 million, a price-to-earnings ratio of -4.44 and a beta of 0.84.
Analyst Upgrades and Downgrades
Separately, Maxim Group initiated coverage on BioHarvest Sciences in a research note on Wednesday, December 18th. They issued a "buy" rating and a $12.00 target price for the company.
Check Out Our Latest Analysis on BioHarvest Sciences
BioHarvest Sciences Company Profile
(
Get Free Report)
BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.
Further Reading
Before you consider BioHarvest Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioHarvest Sciences wasn't on the list.
While BioHarvest Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
